Siemens Healthineers AG

$ 34.23 -0.58 %

Siemens Healthineers AG, a subsidiary of Siemens Aktiengesellschaft with its headquarters in Erlangen, Germany, is a global leader in medical technology. The company develops, produces, and distributes a comprehensive portfolio of diagnostic and therapeutic products and services, catering to healthcare providers worldwide. Its operations are organized into four distinct business segments. The Imaging segment delivers advanced medical imaging systems, encompassing magnetic resonance imaging (MRI), computed tomography (CT), X-ray technology, molecular imaging, and ultrasound solutions. The Diagnostics segment focuses on providing in-vitro diagnostic products and services for laboratory, molecular, and point-of-care applications, alongside workflow optimization tools and informatics solutions for healthcare facilities. Varian, another key segment, specializes in cancer care, offering cutting-edge technologies, services, and integrated solutions to hospital oncology departments. This includes enhancing workflow efficiency, providing clinical services and consulting, and deploying digital platforms for treatment and therapy management. Lastly, the Advanced Therapies segment supplies sophisticated products designed to facilitate image-guided minimally invasive treatments across various medical fields, such as cardiology, interventional radiology, and surgery. Its offerings include angiography systems, mobile C-arms, and a robotic-assisted platform specifically for endovascular coronary and peripheral vascular procedures. Beyond these core offerings, Siemens Healthineers also provides a suite of essential support services, such as equipment performance management, clinical education and e-learning programs, asset management, managed departmental services for laboratories and healthcare facilities, and expert consulting and digital health services.

CEO: Bernhard Montag - https://www.siemens-healthineers.com

Price objectif

-

Recommandation

Buy

DCF

$ 59.65

Loading data...

SHL.DE vs S&P500

Loading data...

No data available.

Quick ratio

0.75

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

18.40

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

1.86

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

11.59 %

reflects reasonable profitability, showing good use of equity.

ROIC

7.07 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

6.66

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.84

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

1.79

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

53.34 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
8 indicates good financial health
Altman score
1.74 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.15 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.34 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.